IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
+2.7%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$415M
AUM Growth
+$415M
(+9.5%)
Cap. Flow
+$33.4M
Cap. Flow
% of AUM
8.06%
Top 10 Holdings %
Top 10 Hldgs %
52.35%
Holding
76
New
10
Increased
22
Reduced
9
Closed
8
Top Buys
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$14.4M |
| 2 |
Amgen
AMGN
|
$14.3M |
| 3 |
Illumina
ILMN
|
$10.9M |
| 4 |
Incyte
INCY
|
$9.18M |
| 5 |
Travere Therapeutics
TVTX
|
$8.73M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$17.8M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$14M |
| 3 |
United Therapeutics
UTHR
|
$7.77M |
| 4 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$7.59M |
| 5 |
Protagonist Therapeutics
PTGX
|
$6.81M |
Sector Composition
| 1 | Healthcare | 98.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $28.1M | 6.78% | 402,784 | – | – |
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $27.7M | 6.69% | 289,500 +82,500 | +40% | +$7.91M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $26M | 6.28% | 237,873 | – | – |
|
|
4
Amgen
AMGN
$155B
| $25.1M | 6.06% | 118,300 +67,300 | +132% | +$14.3M |
|
|
BHVN
5
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $24.5M | 5.91% | 176,400 | – | – |
|
|
SGEN
6
DELISTED
Seagen Inc. Common Stock
SGEN
| $18.6M | 4.49% | 109,700 -35,300 | -24% | -$5.99M |
|
|
7
Incyte
INCY
$16.5B
| $18.6M | 4.48% | 270,360 +133,500 | +98% | +$9.18M |
|
|
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $17.4M | 4.2% | 98,500 +81,600 | +483% | +$14.4M |
|
9
PTC Therapeutics
PTCT
$3.92B
| $16.7M | 4.03% | 449,000 | – | – |
|
|
10
Alnylam Pharmaceuticals
ALNY
$58.5B
| $14.2M | 3.42% | 75,000 -74,000 | -50% | -$14M |
|
11
Vertex Pharmaceuticals
VRTX
$100B
| $14M | 3.38% | 77,222 +12,400 | +19% | +$2.25M |
|
|
12
Illumina
ILMN
$15.8B
| $10.9M | 2.64% | +27,000 | New | +$10.9M |
|
13
Exelixis
EXEL
$10.1B
| $10.3M | 2.49% | 489,534 +388,000 | +382% | +$8.2M |
|
14
Ultragenyx Pharmaceutical
RARE
$2.89B
| $9.29M | 2.24% | 103,100 +43,000 | +72% | +$3.87M |
|
|
TPTX
15
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $9.22M | 2.22% | 138,741 +17,200 | +14% | +$1.14M |
|
|
16
Travere Therapeutics
TVTX
$1.56B
| $9.22M | 2.22% | 380,000 +360,000 | +1,800% | +$8.73M |
|
17
Harmony Biosciences
HRMY
$2.12B
| $9.02M | 2.18% | 236,000 +70,000 | +42% | +$2.68M |
|
18
Supernus Pharmaceuticals
SUPN
$2.53B
| $7.93M | 1.91% | 297,500 +95,064 | +47% | +$2.54M |
|
19
Biogen
BIIB
$19.4B
| $7.21M | 1.74% | 25,500 -23,000 | -47% | -$6.5M |
|
|
CCXI
20
DELISTED
ChemoCentryx, Inc.
CCXI
| $7.13M | 1.72% | 94,300 +36,200 | +62% | +$2.74M |
|
21
KalVista Pharmaceuticals
KALV
$678M
| $6.69M | 1.61% | 383,233 +100,000 | +35% | +$1.74M |
|
22
Insmed
INSM
$28.8B
| $6.64M | 1.6% | 241,100 +141,000 | +141% | +$3.88M |
|
23
uniQure
QURE
$896M
| $5.83M | 1.41% | 182,194 -133,306 | -42% | -$4.27M |
|
24
Jazz Pharmaceuticals
JAZZ
$7.75B
| $5.76M | 1.39% | 44,200 +24,200 | +121% | +$3.15M |
|
25
Ascendis Pharma
ASND
$11.8B
| $4.69M | 1.13% | 29,400 +15,600 | +113% | +$2.49M |
|